Loading
Catumaxomab (Korjuny) is an antibody infused into the abdominal cavity to control malignant ascites, the build-up of fluid caused by cancers such as ovarian and stomach cancer, in people whose other treatments have stopped working.
Catumaxomab was the first bispecific antibody approved anywhere, authorised in the EU in 2009 as Removab for malignant ascites in EpCAM-positive carcinomas on a randomised trial against paracentesis alone in which puncture-free survival was quadrupled. Its marketing authorisation was withdrawn in 2017 for commercial reasons after the original company failed, and a new authorisation was granted to Korjuny in February 2025 for intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas not eligible for further systemic anticancer therapy. It is given as four intraperitoneal infusions over about ten days. Cytokine release-type reactions (fever, nausea, vomiting, abdominal pain) are almost universal and hepatic enzyme rises are common; it has never been approved in the US.
1.One arm of Catumaxomab binds EpCAM on the cancer cell.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| EU | 2009 | Malignant ascites in EpCAM-positive carcinomas when standard therapy is unavailable (Removab; withdrawn 2017) |
| EU | 2025 | Intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas not eligible for further systemic therapy (Korjuny) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Catumaxomab" OR ABSTRACT:"Catumaxomab" OR TITLE:"Korjuny" OR ABSTRACT:"Korjuny" OR TITLE:"Removab 2009 to 2017" OR ABSTRACT:"Removab 2009 to 2017") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Catumaxomab, not a curated reading list.
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag supportive.
Shares Ovarian cancer and the tag supportive.
Shares Ovarian cancer and the tag supportive.
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag supportive.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag supportive.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag supportive.
Shares T-cell engagers (bispecific) and the tag supportive.
Shares Pancreatic ductal adenocarcinoma and the tag supportive.